A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Pfizer
Beijing Biotech
Eisai Inc.
AstraZeneca
M.D. Anderson Cancer Center
Qurient Co., Ltd.
Case Comprehensive Cancer Center
Essen Biotech
Essen Biotech
DualityBio Inc.
Grey Wolf Therapeutics
Takeda
Second Life Therapeutics
Bristol-Myers Squibb
West China Hospital
Eureka Therapeutics Inc.
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
The First Affiliated Hospital of Xiamen University
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
ModeX Therapeutics, An OPKO Health Company
Thomas Jefferson University
University Hospital, Antwerp
Eureka Therapeutics Inc.
Intensity Therapeutics, Inc.
Omega Therapeutics
Biotheus Inc.
University Health Network, Toronto
Second Affiliated Hospital of Guangzhou Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fusion Pharmaceuticals Inc.
Klus Pharma Inc.
City of Hope Medical Center
University of Rochester
Novartis
Basilea Pharmaceutica
Chongqing Precision Biotech Co., Ltd
ImmVira Pharma Co. Ltd
Big Ten Cancer Research Consortium
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Eisai Inc.
University Medical Centre Ljubljana
Nanobiotix
M.D. Anderson Cancer Center
Eli Lilly and Company
University of Texas Southwestern Medical Center
University Health Network, Toronto
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center